Targeted cancer therapies are drugs or other substances that block the growth and spread of cancer by interfering with specific molecules that are involved in the growth, progression and spread of cancer.

Each personalized gene profile provides information on current FDA-approved treatment options proven effective for the tumor DNA mutations identified.

Sources: cancer.gov and fda.gov

ABL1
Bosutinib
Busulfan
Dasatinib
Imatinib
Nilotinib
Omacetaxine
Ponatinib

ALK
Ceritinib
Crizotinib

BRAF
Dabrafenib
Trametinib
Vemurafenib

EGFR
Afatinib
Cetuximab
Erlotinib
Gefitinib
Lapatinib
Panitumumab
Vandetanib

ERBB2
Ado-Trastuzumab
Emtansine
Everolimus
Lapatinib
Pertuzumab
Trastuzumab

FLT3
Cabozantinib
Ponatinib

JAK2
Ruxolitinib

JAK3
Tofacitinib

KIT
Axitinib
Cabozantinib
Imatinib
Pazopanib
Regorafenib
Sorafenib

KRAS
Cetuximab
Panitumumab

MET
Cabozantinib
Crizotinib

PDGFRA
Axitinib
Imatinib
Pazopanib
Sorafenib

RET
Cabozantinib
Regorafenib
Vandetanib

ALK GENE FUSION
Alectinib
Brigatinib
Crizotinib
Ceritinib

ROS1 GENE FUSION
Crizotinib

PD-L1 EXPRESSION
Pembrolizumab
Nivolumab

MSI-H
Pembrolizumab
Nivolumab


Genes below have no FDA-approved drugs at this time.

AKT1
APC
CDKN2A
CTNNB1
EZH2
FBXW7
FGFR1
FGFR2
GNA11
GNAQ
HRAS
IDH1

MPL
NOTCH1
NPM1
NRAS
PIK3CA
PTEN
RB1
SMAD4
SRC
STK11
TP53